{"abstract":"The Food and Drug Administration (FDA) is announcing the termination and reestablishment of the Peripheral and Central Nervous System Drugs Advisory Committee by the Commissioner of Food and Drugs (the Commissioner). The Peripheral and Central Nervous System Drugs Advisory Committee was terminated on June 4, 2026, because its charter was not renewed on or before that expiration date. The Commissioner has determined that it is in the public interest to reestablish the Peripheral and Central Nervous System Drugs Advisory Committee for 2 years from the date it is reestablished.","action":"Notice; termination and reestablishment of Federal advisory committee.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Food and Drug Administration","name":"Food and Drug Administration","id":199,"url":"https://www.federalregister.gov/agencies/food-and-drug-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/199","parent_id":221,"slug":"food-and-drug-administration"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2026/07/23/2026-14829.html","cfr_references":[],"citation":"91 FR 46444","comment_url":null,"comments_close_on":null,"correction_of":null,"corrections":[],"dates":"Authority for the Peripheral and Central Nervous System Drugs Advisory Committee will reestablish on July 30, 2026.","disposition_notes":null,"docket_ids":["Docket No. FDA-2026-N-0008"],"dockets":[{"supporting_documents":[],"agency_name":"FDA","documents":[{"comment_count":0,"comment_start_date":"2026-07-23","updated_at":"2026-07-23T10:56:56.162-04:00","comment_url":"https://www.regulations.gov/commenton/FDA-2026-N-0008-0009","allow_late_comments":false,"id":"FDA-2026-N-0008-0009","comment_end_date":null,"regulations_dot_gov_open_for_comment":false}],"supporting_documents_count":0,"id":"FDA-2026-N-0008","title":"Advisory Committee"}],"document_number":"2026-14829","effective_on":null,"end_page":46446,"executive_order_notes":null,"executive_order_number":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2026/07/23/2026-14829.xml","html_url":"https://www.federalregister.gov/documents/2026/07/23/2026-14829/advisory-committee-peripheral-and-central-nervous-system-drugs-advisory-committee-termination-and","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2026-14829?publication_date=2026-07-23","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2026-07-23/2026-14829/mods.xml","not_received_for_publication":null,"page_length":3,"page_views":{"count":236,"last_updated":"2026-09-21 02:15:06 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-07-23/pdf/2026-14829.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-14829.pdf?1784724308","publication_date":"2026-07-23","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2026/07/23/2026-14829.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"supporting_documents":[],"comments_count":0,"agency_id":"FDA","comments_url":"https://www.regulations.gov/docketBrowser?rpp=50&so=DESC&sb=postedDate&po=0&dct=PS&D=FDA-2026-N-0008","supporting_documents_count":0,"docket_id":"FDA-2026-N-0008","document_id":"FDA-2026-N-0008-0009","regulation_id_number":null,"title":"Advisory Committee","checked_regulationsdotgov_at":"2026-07-24T17:55:05Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":46444,"subtype":null,"title":"Advisory Committee; Peripheral and Central Nervous System Drugs Advisory Committee; Termination and Reestablishment","toc_doc":"Peripheral and Central Nervous System Drugs Advisory Committee","toc_subject":"Charter Amendments, Establishments, Renewals and Terminations","topics":[],"type":"Notice","volume":91}